Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy. (Q50642405)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Yuki Nakajima

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Naoto Tomita

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Reina Watanabe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Yasufumi Ishiyama

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Eri Yamamoto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Daisuke Ishibashi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Megumi Itabashi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Satoshi Koyama

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Ayumi Numata

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Hirotaka Takasaki

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Rika Kawasaki

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Hideyuki Kuwabara

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Masatsugu Tanaka

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Chizuko Hashimoto

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Katsumichi Fujimaki

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Rika Sakai

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Shigeki Motomura

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Yoshiaki Ishigatsubo

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

21 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

185

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

13 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Serum beta 2 microglobulin in malignant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Investigation of the freely available easy-to-use software 'EZR' for medical statistics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0185-3

Biological markers may add to prediction of outcome achieved by the International Prognostic Score in Hodgkin's disease

21 January 2018

1 reference

12 December 2020

The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma

1 reference

12 December 2020

Prognostic role of serum beta 2-microglobulin in Hodgkin's disease

1 reference

12 December 2020

Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients

1 reference

12 December 2020

Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease

1 reference

12 December 2020

Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas findings in a multicenter study and experience in selected patients

1 reference

12 December 2020

Early death in patients diagnosed with non-Hodgkin's lymphoma

1 reference

12 December 2020

10.1007/S12032-014-0185-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25142947%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference